Belite Bio, Inc. is seeking priority review for a drug application from the FDA and disclosed stock sales via SEC filing.
4 reports, 1 independent
Updated Thu 00:00
No new developments lately
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Belite Bio, Inc. is seeking priority review for a drug application from the FDA and disclosed stock sales via SEC filing.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Belite Bio, Inc. is subject to analyst rating reports and an insider sold company stock.1 source
Belite Bio filed for FDA priority review and disclosed stock sales to the SEC.1 source
Keep exploring
The entities involved
Related events
- The FDA is currently reviewing new drug applications for market entry.
- Litigation regarding FDA approval process.
- The FDA recommended advancement for a new drug application submitted by a company.
- Pulse Biosciences disclosed stock transactions via a legal filing with the SEC.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.